Skip to main content

Table 3 Associations of confirmed SARS-CoV-2 infection. Univariable analysis

From: Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

  OR 95% CI p
Age ≥ 58 years 1.12 0.49 to 2.55 0.79
Male gender 1.04 0.44 to 2.46 0.93
Smoking 1.36 0.45 to 4.12 0.59
BMI
 Underweight Reference   
 Normal weight 0.46 0.05 to 3.88 0.48
 Overweight 0.46 0.05 to 4.18 0.49
 Obese 0.79 0.08 to 7.69 0.84
 Hypertension 2.09 0.87 to 5.06 0.10
 Diabetes 1.28 0.29 to 5.58 0.74
 Home lockdown 0.62 0.26 to 1.50 0.29
 Use of masks and gloves 0.64 0.27 to 1.51 0.30
 Contact avoidance 0.73 0.31 to 1.75 0.48
 Contacts with COVID-19 13.01 5.14 to 32.91 < 0.001
Diagnosis
 SpA Reference   
 PsA 0.37 0.07 to 2.03 0.25
 RA 1.03 0.34 to 3.08 0.96
 Disease duration ≥ 120 months 0.65 0.27 to 1.53 0.32
 PDN 2.89 1.26 to 6.62 0.01
PDN dose
 0 mg/day Reference   
 < 2.5 mg/day 1.41 0.39 to 5.15 0.61
 ≥ 2.5 mg/day 4.22 1.74 to 10.23 0.001
 HCQ 1.21 0.45 to 3.29 0.70
 csDMARDs 1.80 0.76 to 4.27 0.18
 b/tsDMARDs 0.46 0.20 to 1.06 0.07
  1. BMI body mass index, SpA spondyloarthritis, PsA psoriatic arthritis, RA rheumatoid arthritis, PDN prednisone, HCQ hydroxychloroquine, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, b/ts DMARDs biological/targeted synthetic disease-modifying anti-rheumatic drugs